Relatively little is known about the epidemiology of carcinoid tumours in contrast to the extensive information available on their biochemical effects and natural history. Accordingly, we have used cancer regtstrations in England from 1979 to 1987, and in Scotland from 1980Scotland from to 1989 Carcinoid tumours were so named by Oberndorfer in 1907 because they resembled carcinomas but were thought to be of a more benign nature (Grahame-Smith, 1972) . Since then the malignant potential of these tumours has been recognised. MacDonald (1956) has suggested that all extra-appendiceal carcinoids should be considered potentially malignant. Carcinoid tumours are the most common tumour of the appendix, the most common gastrointestinal neuroendocrine tumour and the most common form of bronchial adenoma. They may present with non-specific abdominal symptoms, with local symptoms such as haemorrhage or obstruction of the bowel or a bronchus, with evidence of metastasis or with the malignant carcinoid syndrome. This syndrome, first described in 1934, is characterised by facial flushing, bronchoconstriction, episodic diarrhoea and right-sided valvular heart disease (Cassidy, 1934; Grahame-Smith, 1972 England Cancer registration data were obtained from the OPCS on all carcinoid tumours first registered in 1979-87 in English residents. Although the OPCS also holds Welsh data, these could not be used in this study because they rarely include tumour morphology codes. Registrations of carcinoid tumours were identified using morphology codes 8240-8244 from the International Classification of Diseases for Oncology (ICD-O) (WHO, 1976). The tumours had been given either malignant site codes (ICD-9 140-208) (WHO, 1977) or site codes which indicated that their future behaviour was uncertain (ICD-9 235-238). Before 1979, when ICD-8 (WHO, 1%9) was used, tumours of uncertain behaviour were not coded separately from benign tumours and were not recorded by cancer-registries. The majority of carcinoid tumours are of uncertain malignancy. This study, therefore, was restricted to the period after 1979 when only tumours specifically reported as benign by the pathologist would not have been registered.
Carcinoid tumours were so named by Oberndorfer in 1907 because they resembled carcinomas but were thought to be of a more benign nature (Grahame-Smith, 1972) . Since then the malignant potential of these tumours has been recognised. MacDonald (1956) has suggested that all extra-appendiceal carcinoids should be considered potentially malignant. Carcinoid tumours are the most common tumour of the appendix, the most common gastrointestinal neuroendocrine tumour and the most common form of bronchial adenoma. They may present with non-specific abdominal symptoms, with local symptoms such as haemorrhage or obstruction of the bowel or a bronchus, with evidence of metastasis or with the malignant carcinoid syndrome. This syndrome, first described in 1934, is characterised by facial flushing, bronchoconstriction, episodic diarrhoea and right-sided valvular heart disease (Cassidy, 1934; Grahame-Smith, 1972) . It is found in less than 10% of patients with carcinoid tumours in most case series, and generally only after the tumour has metastasised. Many carcinoid tumours are asymptomatic and are found incidentally, for example at appendicectomy or at post-mortem (Berge & Linell, 1976) .
Although a number of aspects of carcinoid tumours have been studied in detail, relatively little is known about their epidemiology and no aetiological factors have been established (Basser & Green, 1991) . It is difficult to derive incidence rates from the many published case series because of uncertain denominators and potential referral biases. The few population-based studies from the UK (Watson et al., 1989; Woods et al., 1990) have not been large enough to analyse risks by age and sex, and there are few populationbased studies from elsewhere (Godwin, 1975; Weiss & Yang, 1987 (Stiller, 1993 Table I ). The natural history of carcinoid tumours is such that the distinction between a malignant tumour and one of potential malignancy is not easily made. On examination of the data, there seemed to be inconsistency among registries in the proportion of cases assigned a malignant, as opposed to an uncertain, site code. Because of this evidence of crossover between the categories we did not analyse malignant tumours separately from those of uncertain behaviour.
As the coding of carcinoid tumours is relatively complex, we conducted a simple telephone survey of registry coding practice for these tumours in England. This showed that similar coding rules existed in all registries. Only two registries did not routinely receive pathology reports on all cancers as well as information from death certificates and other sources. The Thames Registry receives information in electronic format from staff working in the field. In Trent, registrations are generated by hospital records staff from information held on hospital information systems and the registry then obtains pathological information from the clinical notes or from the clinician directly. For the surveillance of carcinoid tumours hospital activity information systems are likely to be less sensitive than a system which includes direct reporting by pathology laboratories.
In order to estimate the completeness of registration of carcinoid tumours using information already to hand, English registries were searched for records of 17 patients known by one of us (D.G.S.) to have had a carcinoid tumour diagnosed histologically. A more formal test of completeness was beyond the scope of this study. Scotland Data were obtained from the Scottish Common Services Agency on all carcinoid tumours first registered in the years 1980-89 in residents of Scotland. Tumours with malignant or uncertain site codes, ICD-9 140-208 and 235-238, were included. Because the number of tumours was smaller than for England, they were not analysed by site.
Statistical methods
Overall rates were directly age standardised using the population of England and Wales in 1981 as a standard for both English and Scottish data. Confidence intervals were calculated using the Poisson approximation to the normal distribution.
Results

England
In the period 1979-87, there were 3,382 carcinoid tumours registered in England. Age-standardised registration rates per 100,000 per year (95% Cl) were 0.71 (0.68-0.75) in men and 0.87 (0.83-0.91) in women. The distribution of these tumours by site and behaviour, which was similar in males and females, is given in Table I . Figure 1 shows age-and sex-specific mean annual registration rates for all sites. The incidence rates increased with age in each sex, but declined sharply after 80 years. Incidence rates were consistently greater for females than males throughout the reproductive years. There was a sharp peak in women aged 15-19 years which was not seen in males. After the age of 50 years the sex difference was reversed. Analysis of information from each registry separately (data not reported) showed that these sex differences were not due to anomalous results from any one registry. Figures 2 and 3 show similar data separately for gastrointestinal and thoracic tumours respectively. Gastrointestinal tumours were relatively more common in younger age groups compared with thoracic tumours. The peak of incidence in women aged 15-19 years was only seen for gastrointestinal tumours. The female excess in the reproductive years was apparent in both gastrointestinal and thoracic tumours. (Godwin, 1975 study reported to date used data from cancer registries covering approximately 10% of the population of the US (Godwin, 1975) . In that study of 970 cases, age-standardised incidence rates of carcinoid tumour per 100,000 per year were 1.3 in males and 1.6 in females. Thus, Godwin found, as we did, an excess of tumours in women, particularly tumours of the appendix (F:M ratio 3.3:1), which he attributed to a higher rate of laparotomy and incidental diagnosis in women. He also found a female excess for bronchial carcinoids (F:M ratio 1.25:1) as at younger ages in our study. Godwin did not report rates or sex ratios by age group but showed that the average age of patients with appendiceal tumours (36 years) was less than for other sites (50 years for bronchial tumours, 63 years for tumours of the small intestine), which is also consistent with our results. Another American study used cancer registry data but only looked at cancers of the small intestine (Weiss & Yang, 1987) . The unadjusted all-ages incidence rate of these tumours was 0.29 per 100,000 per year (n = 542). Incidence rates rose sharply after the age of 30 years.
We are aware of only two population-based studies of carcinoid tumours from the UK. In Northern Ireland, from 1970 to 1985, 318 gastrointestinal carcinoid tumours were ientified (Watson et al., 1989) (Thompson et al., 1985) (Primatesta & Goldacre, 1994) . Admissions for gall stones are also much more common in women than men, the F:M ratio in the age range 15-39 years was 5.7:1, again in the Oxford region (M. Goldacre, personal communication (Primatesta & Goklacre, 1994) , which was rather less than the F:M ratio of incidence of abdominal carcinoids at the same age in England, which was 2.14. A recently published case series reported that 22 out of 41 appendiceal carcinoid tumours presented with acute abdominal symptoms suggestive of appendicitis (Roggo et al., 1993) and, of the 41 tumours, 33 (80%) were in women. As less than halfof the tumours were found incidentally it seems unlikely that the female excess was entirely explained by diagnostic bias. The most convincing evidence is that in our study and elsewhere bronchial carcinoids are also more common in women than men under 50 years. An age-dependent diagnostic bias in favour of females for bronchial tumours seems unlikely. Thus the data suggest that the female excess at reproductive ages, and perhaps also the peak ratio at 15-19, reflects a true sex difference in incidence in addition to a diagnostic bias in favour of females.
Several tumours arising in sites which are not sex specific show marked age-specific sex differences in incidence, e.g. cancers of the breast, thyroid and descending colon (dos Santos Silva & Swerdlow, 1993) , and seem likely to be aetiologically influenced by sex hormones. We have shown that a sex differential is also present for carcinoid tumours, suggesting that endogenous hormones, particularly around the time of puberty, might be important in their aetiology. Oestrogen receptor protein has been identified in carcinoid tumours (Keshgegian & Wheeler, 1980) . This finding led to trials of anti-oestrogen therapy in the carcinoid syndrome. There was some early success (Myers et al., 1982) , although a later study of 16 patients with metastatic carcinoid tumours showed no benefit from treatment with tamoxifen (Moertel et al., 1984) . The epidemiological information presented in this paper suggests that the role of sex hormones as factors in the growth and development of carcinoid tumours should be investigated further. 
